Biotech Startups

Feel Therapeutics develops digital biomarkers and digital health solutions for mental health treatment, designed to function as standalone programs or alongside medications. The company operates within the digital precision medicine space and partners with pharmaceutical and biotech firms on clinical development and commercialization.

5 investors

Cell Microsystems develops laboratory instruments and platforms for cell engineering, culture, isolation, and analysis, including single-cell sorting, 3D cell culture, cell counting, tissue dissociation, and automated electrophysiology. Its tools serve life-science researchers and biopharma labs working on cell line development, drug discovery, and organoid/stem cell research.

5 investors

Fractyl develops therapies for obesity and type 2 diabetes, focusing on non-drug-based approaches rooted in understanding metabolic disease mechanisms. The company serves patients and the physician community seeking alternatives to lifelong pharmaceutical treatments.

5 investors

FREDsense builds biologically-based sensing technology that uses synthetic biology, electrochemistry, and electrical engineering to monitor water quality. It serves clients addressing water and wastewater challenges in the cleantech and environmental monitoring space.

5 investors

G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.

5 investors

GCTx develops an induced pluripotent stem cell (iPSC) programming platform called TFome™ that uses synthetic biology, gene editing, and machine learning to improve cell therapy development and scaling. The platform is designed to expand patient access to cell therapies across various therapeutic areas.

5 investors

GelSana Therapeutics develops zwitterionic polymer-based biomaterials for wound care, addressing excess sustained inflammation that impedes healing. Its first product, CleraFlex, is a shelf-stable wound dressing designed to reduce inflammation, repel bacteria, balance moisture, and provide a protective barrier.

5 investors

General Control is developing programmable, multiplexed epigenetic editing therapies designed to control the expression of several genes at once. It targets complex diseases with many interacting phenotypes, such as Alzheimer's and sarcopenia.

5 investors

Generate:Biomedicines develops protein-based therapeutics using artificial intelligence and machine learning in a field it calls Generative Biology, combining computational protein design with biological engineering. The company creates new drugs on demand across diverse biologic modalities for immunology, oncology, infectious disease, and vaccines.

5 investors

Georgiamune is a biopharmaceutical company developing targeted immunomodulator drugs that activate or down-modulate immune signaling pathways to treat cancer and autoimmune diseases. It operates a target discovery platform that supports a pipeline of first-in-class assets.

5 investors

Goryo Chemical develops fluorescence-based technology to visualize diseases and support diagnosis and treatment. The company applies chemistry to medical and healthcare applications for patients and clinicians.

5 investors

Gracell Biotechnologies develops cell therapy manufacturing platforms and treatments, with a focus on CAR-T cell therapies for cancer and autoimmune diseases. The company operates manufacturing facilities in China and was acquired by AstraZeneca in February 2024.

5 investors

Green Earth Institute is a Japanese company operating a corporate office in Tokyo and a research center in Kisarazu, Chiba. The available page content only lists office and research center locations with access directions, giving limited detail on the company's business.

5 investors

Grove Biopharma develops Bionic Biologics, a drug discovery platform combining AI-enabled molecular design, precision polymer chemistry, and experimental biology to target protein-protein interactions that are inaccessible to conventional therapeutics. The platform creates cell-penetrant, protein-scale molecules designed to engage intracellular targets for pharmaceutical applications.

5 investors

HAYA Therapeutics develops precision RNA medicines that target long non-coding RNAs (lncRNAs) in the regulatory genome to reprogram disease at the level of cell state, with a lead program in cardiac fibrosis and work in obesity and metabolic disease. The biotech company builds a regulatory genome platform to discover tissue- and cell-specific lncRNA targets and turn them into oligonucleotide-based therapies.

5 investors

Helogen builds fully automated, AI-driven factories in orbit that produce high-value biomaterials impossible to manufacture on Earth by leveraging the microgravity environment. The company targets pharmaceutical, biotech, and health-focused industries, enabling superior product purity and carbon-positive manufacturing at unprecedented scale.

5 investors

Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding. The company uses biologics and precision-designed therapeutic candidates to stabilize coagulation proteins and prevent bleeding events.

5 investors

Hexagon Bio develops novel payload mechanisms for antibody-drug conjugates (ADCs) aimed at overcoming resistance to current cancer treatments and expanding ADC indications. The company focuses on targeted cytotoxic therapy for cancer, drawing on human therapeutics derived from metagenomes.

5 investors

HighLife develops a transcatheter mitral valve replacement (TMVR/TSMVR) technology for patients with moderate to severe mitral regurgitation, implanted in a beating heart while preserving the native valve structure. The medical device company operates across Europe, the USA and Australia, with valves manufactured in Irvine, California.

5 investors

XOMA Royalty is a biotech royalty aggregator that acquires the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates, providing sellers with non-dilutive, non-recourse funding. It holds a portfolio of 120+ assets and serves biotech companies developing drug candidates.

5 investors

Hilltop Bio develops bioscaffold and therapeutic products for veterinary use, including wound care, joint health, soft tissue repair, and ophthalmic solutions for equine and small animal patients.

5 investors

HistoWiz offers histopathology services for cancer researchers, processing mailed tissue specimens and producing digital whole-slide images accessible through a cloud-based virtual microscope. Its web platform adds online collaboration tools, data management, and experimental pathology expertise for medical scientists and research pathologists.

5 investors

HotHouse Therapeutics uses artificial intelligence and synthetic biology to reprogram plant biosynthetic pathways to create novel pharmaceutical compounds not achievable through traditional chemical synthesis.

5 investors

Qoniq combines tailored AI analytics with expert guidance to help Medical Affairs and Scientific Affairs teams analyze large volumes of publications and datasets, surface patterns, and generate industry-standard, well-sourced scientific reports. It serves life sciences and pharmaceutical organizations for tasks such as post-marketing surveillance and scientific engagement.

5 investors